Clinical trial
Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated…
NCT02137850 · Novo Nordisk A/S, Industry · Completed
Key facts
| NCT number | NCT02137850 |
|---|---|
| Title | Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A |
| Official title | An Open-label Single-arm Multicentre Non-controlled Phase 3a Trial Investigating Safety and Efficacy of N8-GP in Prophylaxis and Treatment of Bleeding Episodes in Previously Untreated Paediatric Patients With Severe Haemophilia A |
| Acronym | pathfinder™6 |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Congenital Bleeding Disorder, Haemophilia A |
| Intervention type | Drug |
| Interventions | turoctocog alfa pegol |
| Enrollment | 124 |
| Start date | Jun 26, 2014 |
| Primary completion | Jun 7, 2023 |
| Completion | Jun 7, 2023 |
| First posted | May 14, 2014 |
| Last update posted | Dec 23, 2025 |
| Countries | Algeria, Argentina, Australia, Austria, Bulgaria, Canada, France, Germany, Greece, Israel, Italy, Japan and 11 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: